Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04886284 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia

Study acronym: CERT
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 6 to 7v11
  2. Study sites: 5 to 6v10
  3. Primary completion pushed from Apr 2026 to Apr 2027
    • Study completion pushed from Jul 2026 to Jul 2027
    v9
  4. Study sites revised (5)v8
  5. Primary completion date: Apr 2025 to Apr 2026
    • Study sites: 4 to 5
    • Study completion date: Jul 2025 to Jul 2026
    v7
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 1 to 4v6
  2. Site contact updatedv5
  3. Trial status: Not Yet Recruiting to Recruitingv4 Show 6 more changesShow less
    • Primary completion date: Mar 2023 to Apr 2025
    • Start date changed from estimate of Jul 2022 to May 20, 2024
    • Study completion date: Jul 2023 to Jul 2025
    • Eligibility criteria expanded, about 28 words
    • Site details revised
    • Publications: 7 to 8
  4. Primary completion date: Feb 2022 to Mar 2023
    • Start date: Feb 2022 to Jul 2022
    • Study completion date: May 2022 to Jul 2023
    v3
  5. Start date: Jul 2021 to Feb 2022
    • Primary completion date: Jul 2022 to Feb 2022
    • Study completion date: Oct 2022 to May 2022
    • Secondary endpoints: 8 to 11
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
There is a variety of in vitro, in vivo (animal model), and human case series data which suggests that the addition of ertapenem to cefazolin could improve outcomes in methicillin-susceptible S. aureus bacteremia. No randomized controlled trial has been performed. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)
Trial Details
NCT Number NCT04886284
Lead Sponsor Todd C. Lee MD MPH FIDSA
Conditions
(from sponsor)		 Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia, Staphylococcal Sepsis, Staphylococcus Aureus Endocarditis
Related terms Bacteremia, Staphylococcal Infections
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov